Logo

Join us as the ClinGen Somatic and VICC Virtual Molecular Tumor Board teams up with The American College of Medical Genetics and Genomics for an innovative CME case series. This series is intended as a forum to share multidisciplinary experiences in cancer genetics around the world to better understand cancer variant detection methods, genomic interpretation, and cancer patient management.

Upcoming Events:

January 

28

Cases in Precision Oncology: Highlights from the 2024 ClinGen Somatic Cancer and VICC Virtual Molecular Tumor Board Case Series 

11:00am - 12:00pm ET

This CME Case Series reflects the work of molecular tumor boards by featuring an interdisciplinary discussion of cases that are subject to comprehensive molecular characterization using a variety of advanced technologies. . The molecular characterization of tumor samples ranges from methods on the genomic level to recent advances in proteomics. The field is advancing rapidly, and more and more approaches will translate from basic research to clinical care. In this session, we will summarize the variety of methods described in previous virtual molecular tumor boards and highlight the most interesting cases from 2024. In addition, we will give an outlook on topics to come in 2025.

February

25

Chromosomal Mimicry in Hematologic Malignancies 

11:00am - 12:00pm ET

Detection of structural variants (SVs) represents a critical component in the diagnostic evaluation and treatment of many hematologic malignancies. Whereas clinical SV testing mainly consists of traditional cytogenetic methodologies, technological innovations have led to alternative approaches with improved resolution. Using a plurality of molecular methodologies including targeted RNA-sequencing, Optical Genome Mapping (OGM) and Hi-C, we describe ‘chromosomal mimicry’ - a phenomenon in which chromosome morphology resembles a known SV but lacks the expected gene level rearrangement - as an infrequent but recurrent finding with the potential to confound clinical management. Our study highlights the need for assays with gene-level resolution in the diagnostic evaluation of hematologic malignancies.        

March

25

Complementary Use of Circulating Tumor Cell Sequencing and Tumor Sequencing 

11:00am - 12:00pm ET

Dr. Nisha Kanwar from Mayo Clinic, will discuss a case where extensive molecular profiling was used to inform patient management in a solid tumor through both circulating tumor DNA (ctDNA) and solid tumor sequencing. This case will highlight some advantages to performing each of these testing modalities and the overall impact on patient care.  

Free Educational Credits Available.

© 2025 American College of Medical Genetics and Genomics. All rights reserved.

Powered By